Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 21 May 2009, Vol. 113, No. 21, pp. 5250-5253.
Prepublished online as a Blood First Edition Paper on March 11, 2009; DOI 10.1182/blood-2008-09-172668.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Tables
Right arrow All Versions of this Article:
blood-2008-09-172668v1
113/21/5250    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schneider, F.
Right arrow Articles by Spiekermann, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schneider, F.
Right arrow Articles by Spiekermann, K.
Related Collections
Right arrow Myeloid Neoplasia
Right arrow Brief Reports
Right arrow Clinical Trials and Observations
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

MYELOID NEOPLASIA

Brief report

NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)

Friederike Schneider1, Eva Hoster1, Michael Unterhalt1, Stephanie Schneider1, Annika Dufour1, Tobias Benthaus1, Gudrun Mellert1, Evelin Zellmeier1, Stefan K. Bohlander1,2, Michaela Feuring-Buske1,2, Christian Buske1,2, Jan Braess1, Susanne Fritsch1, Achim Heinecke3, Maria C. Sauerland3, Wolfgang E. Berdel4, Thomas Buechner4, Bernhard J. Woermann5, Wolfgang Hiddemann1,2, and Karsten Spiekermann1,2

1 Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital Munich, Munich; 2 Clinical Cooperative Group Acute Leukemias, Helmholtz Center Munich, Munich; 3 Department of Medical Informatics and Biomathematics, and 4 Department of Medicine, Hematology and Oncology, University of Muenster, Muenster; and 5 Klinikum Braunschweig, Braunschweig, Germany

Mutations in the NPM1 gene represent the most frequent genetic alterations in patients with acute myeloid leukemia (AML) and are associated with a favorable outcome. In 690 normal karyotype (NK) AML patients the complete remission rates (CRs) and the percentage of patients with adequate in vivo blast cell reduction 1 week after the end of the first induction cycle were significantly higher in NPM1+ (75% and 80%, respectively) than in NPM1– (57% and 57%, respectively) patients, but were unaffected by the FLT3-ITD status. Multivariate analyses revealed the presence of a NPM1 mutation as an independent positive prognostic factor for the achievement of an adequate day-16 blast clearance and a CR. In conclusion, NPM1+ blast cells show a high in vivo sensitivity toward induction chemotherapy irrespective of the FLT3-ITD mutation status. These findings provide insight into the pathophysiology and help to understand the favorable clinical outcome of patients with NPM1+ AML.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020